punctate inner choroidopathy (PIC) complicated with choroidal neovascularization
Conditions
Interventions
1:intravitreal injection of Anti-VEGF
2:intravitreal injection of Anti-VEGF and post-sclera injection of triamcinolone acetonide
Sponsors
Southwest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 65 years who have signed informed consent for the clinical trial; 2. Diagnosing PIC with CNV: The posterior pole conforms to the pathological manifestations of PIC, fluorescein angiography (FA) is found to have CNV leakage, and optical coherence tomography (OCT) is found to have intraretinal or subretinal fluid or central retinal thickness (CRT) Increased; 3. At least one of the following types of CNV lesions involving the central macular area: central fovea; near fovea; central fovea; optic disc margin (abnormal neovascularization around the optic papilla) and involving the central region of the macula; 4. Study eye BCVA = 24 letters and = 86 letters (approximately equal to 20 / 320 to 20 / 25 of Snellen's eye chart); 5. Visual loss must be caused only by the above type of CNV of PIC.
Exclusion criteria
Exclusion criteria: 1. Systemic history and conditions: (1) uncontrollable hypertension (>140/90 mmHg); (2) hypersensitivity; (3) history of stroke or myocardial infarction within 3 months; (4) use of other studies within 30 days Drugs; (5) use systemic glucocorticoids or anti-VEGF drugs within 6 months; (6) use systemic drugs known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine,tamoxifen, phenothiazine and ethambutol; (7)women patients who are in pregnancy or lactation period. 2. Eye history and conditions (both eyes): (1) any active eye infection; (2) active intraocular inflammation; (3) iris neovascularization or neovascular glaucoma; (4) history of uveitis; ) vitreous macular traction syndrome; (5) unable to obtain a sufficient quality fundus photograph or fluorescein angiography for analysis; (6) unilateral or contralateral BCVA: ETDRS = 24 letters; (7) use any within 3 months Hormone and anti-angiogenic drugs (including any glucocorticoids and anti-VEGF drugs) 3.Eye history and conditions (study eye): (1) uncontrollable high intraocular pressure (IOP = 24 mmHg); (2) glaucoma (cup to disk ratio = 0.8); (3) any confusion of interpretation of the results of the study, damage to vision, Ophthalmic diseases or treatments requiring medication or surgery, including cataracts, retinal vascular occlusion, retinal detachment, macular hole or choroidal neovascularization; (4) structural damage within 0.5 disc diameter from the center of the macula; (5) Combined with AMD, PCV; (6) laser photocoagulation within 3 months; (7) intraocular surgery within 3 months; (8) 6 months, intravitreal injection of hormone therapy; 3 months, eye sugar History of treatment with corticosteroids; (9) intravitreal injection of anti-VEGF drugs within 3 months; (10) history of vitrectomy; (11) CNV caused by pathological myopia; (12) other requirements associated with glucocorticoid therapy Eye condition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular thickness;ETDRs; | — |
Countries
China
Contacts
Public ContactLi Shiying
Dept. Ophthalmology, Southwest Hospital
Outcome results
None listed